Journal
DIAGNOSTIC CYTOPATHOLOGY
Volume 39, Issue 9, Pages 703-710Publisher
WILEY
DOI: 10.1002/dc.21512
Keywords
EGFR; KRAS; PCR; cytology; aspiration
Categories
Funding
- Novel molecular markers in the cytological diagnosis (Regione Campania)
Ask authors/readers for more resources
Recent therapeutic progresses in nonsmall cell lung cancer (NSCLC) and in colorectal cancer (CRC) are based on agents that specifically target the epidermal growth factor receptor (EGFR). To identify the patients most likely to benefit from such therapies, EGFR or KRAS gene mutation tests are mandatory, respectively, in NSCLC and in CRC. In patients with locally advanced or metastatic disease, exploiting cytological samples for these tests avoids not curative surgery. Here, we review the studies that have applied gene mutation assays on cytological samples of NSCLC and CRC to select patients for anti-EGFR therapy. We argue that the standard of quality of gene mutation tests on cytological samples is closely dependent on the extent of the cytopathologist's involvement. Diagn. Cytopathol. 2011; 39: 703-710. (C) 2010 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available